WPLYW CETUKSYMABU NA PROCES APOPTOZY I FAZY CYKLU KOMOREK RAKA PIERSI IN VITRO

Abstract

Author(s): Jolanta Rzymowska, Agnieszka Zbyrad

The aim of the study was to check how cetuximab affects the cell cycle and apoptosis of breast cancer cells. The study was conducted on primary breast cancer cell lines and non-neoplastic cell lines derived from samples collected from patients with histopathologically diagnosed Tp1-2 Np0 Mp0 ductal carcinoma. The effect of this chemotherapeutic agent on cells in the G1, S, G2/M cell cycle phases and on apoptosis of these cells was analyzed in a flow cytometer. Cetuximab, a monoclonal antibody, at a dose of 10 and 100 μg/mL of the culture medium was used for the study. Cetuximab is capable of inducing apoptosis and inhibiting cancer cells in the S, and G2/M cell cycle phases. This cytostatic agent can constitute a potential strategy in phase-dependent treatment of breast cancer. However, it is not effective enough to be used in monotherapy.

Share this article

Editors List

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)

  • Skowronska-Gardas

    Department of Radiotherapy, Oncology Center-Institute (Warsaw, Poland)

  • Serban-Dan Costa

    Head of the Obstetrics and Gynecology Clinic of the University of Otto von Guericke (Magdeburg, Germany)